SCHEMBL14058690

SCHEMBL14058690

COc1ccc(C2CC(c3ccc(NS(=O)(=O)c4ccccc4)cc3)=NN2C(C)=O)cc1

nearest known ligand 0.74

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.74
▸ RAB9A P51151 2/20 0.74
▸ PTGS2 P35354 1/20 0.70
▸ CA1 P00915 6/20 0.66
▸ CA2 P00918 6/20 0.66
▸ CA9 Q16790 5/20 0.66
▸ CA12 O43570 4/20 0.66
▸ CA4 P22748 2/20 0.66
▸ MAOA P21397 2/20 0.66
▸ MAOB P27338 2/20 0.66
▸ MEN1 O00255 3/20 0.65
▸ KMT2A Q03164 3/20 0.65
▸ PKM P14618 1/20 0.61
▸ EGFR P00533 2/20 0.60
▸ ALDH1A1 P00352 1/20 0.59
▸ MAPT P10636 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14058333 0.95 PTGS2 (0.77) NPC1RAB9APTGS2CA1CA2
SCHEMBL14057861 0.92 PTGS2 (0.67) NPC1RAB9APTGS2CA1CA2
SCHEMBL14136240 0.91 PTGS2 (0.72) NPC1RAB9APTGS2CA1CA2
SCHEMBL14136237 0.91 NT5E (0.66) NPC1RAB9APTGS2CA1CA2
SCHEMBL14058334 0.91 PTGS2 (0.71) NPC1RAB9APTGS2CA1CA2
SCHEMBL14058704 0.91 PTGS2 (0.71) NPC1RAB9APTGS2CA1CA2
SCHEMBL14058045 0.91 PTGS2 (0.71) NPC1RAB9APTGS2CA1CA2
SCHEMBL14058030 0.91 PTGS2 (0.71) NPC1RAB9APTGS2CA1CA2
SCHEMBL14058025 0.91 NPC1 (0.78) NPC1RAB9APTGS2CA1CA2
SCHEMBL14058605 0.91 PTGS2 (0.71) NPC1RAB9APTGS2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed
WO-2012160447-A1 3, 5 -DIPHENYL- SUBSTITUTED PYRAZOLINES FOR THE TREATMENT OF CANCER, PROLIFERATIVE, INFLAMMATORY OR AUTOIMMUNE DISEASES DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — WO disclosed
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — US disclosed
WO-2012160447-A1 3, 5 -DIPHENYL- SUBSTITUTED PYRAZOLINES FOR THE TREATMENT OF CANCER, PROLIFERATIVE, INFLAMMATORY OR AUTOIMMUNE DISEASES DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302609-A1 Pyrazolines for the Modulation of PKM2 PDK2, PDK4, PDK3 NPC1 3749/4885RAB9A 3384/4885PTGS2 1275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback